Chabak Vaccine Research Institute Signs Technology Transfer Contract for Immune Enhancer... Worth 203.1 Billion KRW

Applied to Cancer Treatment Vaccine Developed by Aston Science

[Asia Economy Reporter Kim Ji-hee] ChabioTech affiliate Chavaccine Research Institute has signed a technology transfer agreement for the immune adjuvant 'L-pampo' with Aston Science, a domestic new drug development bio company. Including milestone payments based on clinical completion and sales royalties, the total contract value reaches 203.1 billion KRW.

The immune adjuvant from Chavaccine Research Institute being transferred will be applied to the cancer therapeutic vaccines ‘AST-021p’ and ‘AST-023’ developed by Aston Science. These vaccines are T-cell specific cancer therapeutic vaccines containing peptide antigens derived from the tumor cell-specific protein HSP90. When combined with the immune adjuvant and administered to the human body, these antigens induce a strong immune response against cancer cells.

Chavaccine Research Institute’s L-pampo was confirmed to induce a much stronger immune response compared to other immune adjuvants currently commercialized or in clinical research stages, according to preclinical studies conducted by Aston Science. It is especially expected to be an optimal treatment method for preventing postoperative recurrence in patients with cancers expressing HSP90 and for terminal cancer patients for whom standard treatments are not possible.

Yeom Jeong-seon, CEO of Chavaccine Research Institute, said, “This technology transfer agreement signifies recognition of the excellence of Chavaccine Research Institute’s immune adjuvant,” adding, “We expect expanded collaboration with various pharmaceutical companies developing vaccines.”

This content was produced with the assistance of AI translation services.